Top Markets
#1 Islamic Coin Islamic Coin +151.48%
#2 DOVU DOVU +48.44%
#3 Black Phoenix Black Phoenix +34.78%
#4 Velvet Velvet +31.18%
#5 Cross Cross +22.50%
#6 Akedo Akedo +15.95%
#7 DoubleZero DoubleZero +14.89%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.53%
#9 Fake World Assets Fake World Assets +10.34%
#10 Cap Cap +10.26%
Coin of the day
Islamic Coin Islamic Coin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Classifica tra le azioni #33957
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Prezzo delle azioni
$17.15
Ultima sincronizzazione: 2026-08-03
Capitalizzazione di mercato
$6.51M
Variazione (1 giorno)
9.80%
Variazione (1 anno)
289.77%
Paese
US
Scambia Galera Therapeutics, Inc. (GRTX)

Categoria

Healthcare
Rapporto P/B per Galera Therapeutics, Inc. (GRTX)
Rapporto P/B al August 2026 TTM: 1.53
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Galera Therapeutics, Inc., il rapporto P/B attuale (TTM) è 1.53. Alla fine del 2023, era pari a -0.05.
Storico del rapporto P/B per Galera Therapeutics, Inc. da 2017 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
2026 (TTM) 1.53 -7,767.00%
2024 -0.02 -64.78%
2023 -0.05 -86.64%
2022 -0.37 -81.88%
2021 -2.04 -104.91%
2020 41.59 786.53%
2019 4.69 -311.62%
2018 -2.22 -99.08%
2017 -240.04 0.00%
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 308.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 314.00%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 136.99%
BE